Pentoxifylline, fibrinogen and leukocytes

Area of Science:

• Pharmacology
• Immunology
• Vascular Medicine

Background:

• Pentoxifylline is known to affect plasma fibrinogen levels.
• Arteritis patients often exhibit elevated fibrinogen levels, contributing to vascular inflammation and disease progression.
• The precise mechanism by which pentoxifylline influences fibrinogen in arteritis remains unclear.

Purpose of the Study:

• To investigate the effect of pentoxifylline on plasma fibrinogen levels in patients with arteritis.
• To explore the relationship between changes in fibrinogen and clinical symptom improvement during pentoxifylline therapy.
• To compare the effects of pentoxifylline on fibrinogen in arteritis patients versus healthy volunteers.

Main Methods:

• Ex vivo experiments were conducted on both healthy volunteers and patients diagnosed with arteritis.
• Plasma fibrinogen levels were monitored during pentoxifylline administration.
• Clinical symptoms in arteritis patients were assessed and correlated with fibrinogen level changes.

Main Results:

• Pentoxifylline therapy confirmed a significant decrease in plasma fibrinogen levels in arteritis patients.
• The reduction in fibrinogen levels was positively correlated with the improvement of clinical symptoms in these patients.
• No significant modifications in plasma fibrinogen levels were observed in healthy volunteers receiving pentoxifylline.

Conclusions:

• The observed decrease in fibrinogen in arteritis patients is likely mediated by an indirect mechanism.
• Pentoxifylline's potential role in reducing Tumor Necrosis Factor (TNF) synthesis may contribute to the observed fibrinogen reduction.
• These findings suggest pentoxifylline as a potential therapeutic agent for managing fibrinogen levels and associated symptoms in arteritis.